证券代码： 300239 证券简称：东宝生物 | --- | --- | |------------------|-----------------------| | | 编号：2023-004 | | 投资者关系活动类 | | | 别 | | | | | | | | | | | | 参与单位名称及人 | | | | | | 员姓名 | | | 时间 | | | 地点 | 证 券 网 路 演 中 心" | | | | | 上市公司接待人员 | | | 姓名 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 投资者关系活动主 | | | 要内容介绍 | | | | | | | | | | A+，评级展望稳定， | | | | 3.本次可转债是否有网下发行？ 包头东宝生物技术股份有限公司 投资者关系活动记录表 | --- | |--------------------------------------------------------------------| | 答：尊敬的投资者，您好。本次发行的可转债将向原股东优先配售， | | 原股东 ...

证券代码： 300239 证券简称：东宝生物 包头东宝生物技术股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|------------------------------------|------------------------------------------------------------------| | | | 编号：2023-003 | | 投资者关系活动类 | □ 特定对象调研 | □ 分析师会议 | | 别 | □ 媒体采访 □ | 业绩说明会 | | | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 | | | | 其他 ( | 深交所"踔厉奋发新征程 投教服务再出发"内蒙古站——走进 | | | 上市公司-东宝生物 | 300239) | | 参与单位名称及人 | 深交所投服部；国融证券及个人投资者 | 16 人 | | 员姓名 | | | | 时间 | 2023 年 7 月 14 日(周五 | ) 9:30—11:00 | | 地点 | 东宝生物生态园区研发中心一楼会议室 | | | 上市公司接待人 ...

证券代码： 300239 证券简称：东宝生物 包头东宝生物技术股份有限公司 投资者关系活动记录表 （2023 年内蒙古辖区上市公司投资者集体接待日活动） 编号：2023-002 | 投资者关系活动类 | □特定对象调研 □ 分析师会议 | | --- | --- | | 别 | □ 媒体采访 √ 业绩说明会 | | | 路演活动 □ 新闻发布会 □ | | | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及人 | 参与 年内蒙古辖区上市公司投资者集体接待日活动的投资者 2023 | | 员姓名 | | | 时间 | 2023 年 6 月 9 日 (周五) 下午 15:30~17:00 | | 地点 | 网络远程方式（全景网"投资者关系互动平台"，https://ir.p5w.net） | | 上市公司接待人员 | 董事、总经理刘芳先生；董事、副总经理刘燕女士；副总经理、董事会秘 | | 姓名 | 书单华夷女士 | | | 本次"2023 年内蒙古辖区上市公司投资者集体接待日活动"，公司 | | | 对投资者关心的问题进行了回复： | | | 1、公司在国际市场上的优势和 ...

证券代码：300239 证券简称：东宝生物 公告编号：2023-047 包头东宝生物技术股份有限公司 关于参加内蒙古辖区上市公司 2023 年投资者网上集体接待 日活动的公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，包头东宝生物技术股份有限公司（以下 简称"公司"）将参加由内蒙古证监局、内蒙古上市公司协会与深圳市全景网络 有限公司联合举办的"2023 年内蒙古辖区上市公司投资者集体接待日活动"， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP, 参与本次互动交流，活动时间为 2023 年 6 月 9 日（周五）15:30-17:00。届时公 司董事兼总经理刘芳先生、董事兼副总经理刘燕女士、副总经理兼董事会秘书单 华夷女士将在线就公司 2022 年度业绩、公司治理、发展战略、 经营状况、可持 续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参 与！ 特此公告。 包头东宝生物技 ...

包头东宝生物技术股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 证券代码：300239 证券简称：东宝生物 公告编号：2023-043 包头东宝生物技术股份有限公司 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 2023 年第一季度报告 3.第一季度报告是否经过审计 □是 否 1 包头东宝生物技术股份有限公司 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | （%） | | | 营业收入（元） | 261,319,537.08 | 228,169,864.35 | | 1 ...

证券代码：300239 证券简称：东宝生物 包头东宝生物技术股份有限公司 投资者关系活动记录表 （2022 年度网上业绩说明会） 10、请问公司是否有潜在的投资并购项目？ 尊敬的投资者您好：公司聚焦胶原产业，紧密围绕"胶原+"，创新推进 胶原在"医、健、食、美"全方位深度应用和布局，在发展过程中，也积极寻 求能够匹配公司发展需求的资源，加快发展速度、提高发展质量。感谢您的 关注。 编号：2023-001 投资者关系活动 类别 特定对象调研 分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 其他(电话会议) 参与单位名称及 人员姓名 参与 2022 年度网上业绩说明会的投资者 时间 2023 年 3 月 29 日 15:00-17:00 地点 网络远程方式（全景网"投资者关系互动平台"，https://ir.p5w.net） 上市公司接待人 员姓名 董事长王爱国先生；董事、总经理刘芳先生；独立董事任斌先生；财务总监 郝海青先生；副总经理、董事会秘书单华夷女士 投资者关系活动 主要内容介绍 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网络 远程的方式召开 ...

Financial Performance - The company's operating revenue for 2022 was ¥943,396,998.69, representing a 54.11% increase compared to ¥612,165,671.91 in 2021[25]. - Net profit attributable to shareholders reached ¥109,437,321.14, a significant increase of 199.96% from ¥36,484,130.69 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was ¥100,942,931.19, up 274.97% from ¥26,920,029.36 in 2021[25]. - Cash flow from operating activities increased by 279.25% to ¥195,317,536.56, compared to ¥51,501,086.21 in 2021[25]. - Basic and diluted earnings per share rose to ¥0.1844, reflecting an increase of 185.01% from ¥0.0647 in 2021[25]. - Total assets at the end of 2022 were ¥2,308,113,622.60, a 9.27% increase from ¥2,112,240,503.24 at the end of 2021[25]. - The company's net assets attributable to shareholders increased by 7.44% to ¥1,528,509,817.66 from ¥1,422,692,834.57 in 2021[25]. - In 2022, the company achieved a revenue of CNY 943,396,998.69, representing a year-on-year growth of 54.11%[67]. - The total profit for the year was CNY 131,647,053.37, which is an increase of 216.91% compared to the previous year[67]. - The net profit attributable to the parent company was CNY 109,437,321.14, marking a growth of 199.96% year-on-year[67]. Market Expansion and Strategy - The company is exploring market expansion opportunities, particularly in the health food sector, which is expected to grow significantly[15]. - The management has indicated a positive outlook for future performance, driven by increased demand for health-related products[15]. - The company is considering strategic partnerships and acquisitions to enhance its market position and product offerings[15]. - The company is focusing on expanding its market share in the health and nutrition sectors, which are expected to see further concentration and growth[48]. - The company is actively developing OEM business and providing guidance in market development and packaging design to ensure stable cooperation with clients[86]. - The company plans to implement an integrated production layout to improve capacity utilization and product quality while controlling production costs, focusing on projects like the new hollow capsule industrialization project[162]. - The company aims to enhance its market share in the TO C segment and strengthen its brand influence while optimizing internal operations to improve asset utilization efficiency[156]. - The company intends to expand its TO B product market, particularly in specialized gelatin and collagen protein, leveraging existing customer relationships and enhancing service levels[158]. Research and Development - The company is actively involved in research and development, particularly in the field of collagen production, with plans for a new 2,000-ton project[15]. - The company has established key laboratories and research centers, enhancing its production capabilities for collagen proteins and gelatin, achieving import substitution in the field of gelatin[73]. - The company has developed a diverse range of consumer products under the "Collagen+" series, catering to various health needs across different age groups[55]. - Research and development expenses increased by 99.05% to ¥25,831,595.08, primarily due to the consolidation of the subsidiary Yiqing Bio[106]. - R&D investment amounted to ¥39,472,620.22 in 2022, representing 4.18% of operating revenue, up from 3.93% in 2021[108]. - The company has a strong focus on innovation, with a robust patent portfolio supporting its product development and market expansion strategies[74]. Production Capacity and Operations - The company is focused on expanding its production capacity, with a project to increase gelatin production from 3,500 tons to 7,000 tons annually[15]. - The company has an annual production capacity of 13,500 tons of gelatin and 24 billion capsules, leading the industry in scale[52]. - The subsidiary Yiqing Bio is advancing the "New Intelligent Industrialization Project for Hollow Capsules," aiming for an annual production capacity of nearly 70 billion capsules upon completion[52]. - The company is currently implementing a project to expand the production capacity of new intelligent hollow capsules to 30 billion capsules annually[69]. - The company has established a comprehensive production quality management system, certified by FSSC22000 and ISO standards[70]. Governance and Compliance - The company has established a robust governance structure, ensuring compliance with regulatory requirements and enhancing shareholder value[5]. - The board of directors consists of 7 members, including 3 independent directors, and operates under various committees to ensure compliance and effective governance[178]. - The company has implemented a performance evaluation and incentive mechanism, including an employee stock ownership plan to enhance cohesion and growth[178]. - The company maintains transparent communication with investors through various channels, ensuring timely and accurate information disclosure[179]. - There are no significant discrepancies between the company's governance practices and the regulations set forth by the China Securities Regulatory Commission[179]. Risks and Challenges - The company has outlined potential risks and corresponding countermeasures in the section discussing future development prospects[5]. - The company acknowledges the risk of intensified market competition and aims to enhance product innovation and service capabilities to maintain market share[167]. - The company is addressing the risk of raw material price fluctuations by conducting market research and implementing differentiated procurement strategies to stabilize costs[168]. - Regulatory risks are increasing in the pharmaceutical and health food sectors, necessitating enhanced market and policy research to adapt to new regulations[172]. Sustainability and Social Responsibility - The management team emphasized a commitment to sustainability, with plans to implement eco-friendly practices across all operations by the end of 2023[195]. - The company is committed to continuous improvement in its production processes and environmental sustainability, as evidenced by its new wastewater treatment systems[76]. Financial Management and Investments - The company raised a total of RMB 407,281,700.00 in funds, with a net amount of RMB 396,693,480.24 after deducting issuance-related expenses of RMB 10,588,219.76[139]. - The company has long-term borrowings of CNY 152,000,000.00, which constitutes 6.59% of total liabilities, indicating a new financing strategy[117]. - The company reported an investment amount of ¥155,905,672.96 in 2022, a decrease of 53.70% compared to the previous year's investment of ¥336,730,348.40[126]. - The company has not engaged in any securities or derivative investments during the reporting period[136][137].